
Silence Therapeutics plc SLN
$ 19.77
0.51%
Country |
|
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
142 M |
Market Cap[1] |
$ 2.8 B |
EBITDA (LTM) |
$ -49.6 M |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
SIGA Technologies
SIGA
|
$ 3.16 | 1.12 % | $ 226 M | Nasdaq Global Select Market | ||
|
NeuBase Therapeutics
NBSE
|
- | -1.56 % | $ 12.3 M | Nasdaq Global Select Market | ||
|
Olema Pharmaceuticals
OLMA
|
$ 6.61 | 3.04 % | $ 575 M | Nasdaq Global Select Market | ||
|
Sol-Gel Technologies Ltd.
SLGL
|
$ 70.54 | 1.57 % | $ 197 M | Nasdaq Global Select Market | ||
|
Deciphera Pharmaceuticals
DCPH
|
- | - | $ 2.18 B | Nasdaq Global Select Market,SPB | ||
|
Arena Pharmaceuticals
ARNA
|
- | -6.81 % | $ 3.04 B | Nasdaq Global Select Market,SPB | ||
|
Scopus BioPharma
SCPS
|
- | -48.37 % | $ 3.71 M | Nasdaq Global Select Market | ||
|
Syndax Pharmaceuticals
SNDX
|
$ 13.21 | -1.42 % | $ 1.14 B | Nasdaq Global Select Market | ||
|
Soligenix
SNGX
|
$ 0.35 | -4.08 % | $ 1.82 M | Nasdaq Capital Market | ||
|
scPharmaceuticals
SCPH
|
- | - | $ 218 M | Nasdaq Global Select Market | ||
|
Spruce Biosciences
SPRB
|
$ 43.74 | -3.12 % | $ 33.5 M | Nasdaq Global Select Market | ||
|
Spero Therapeutics
SPRO
|
$ 1.07 | -4.05 % | $ 59.9 M | Nasdaq Global Select Market | ||
|
Entasis Therapeutics Holdings
ETTX
|
- | - | $ 105 M | Nasdaq Global Market | ||
|
Athersys
ATHX
|
- | 3.77 % | $ 22.4 M | Nasdaq Capital Market | ||
|
Sarepta Therapeutics
SRPT
|
$ 17.99 | 0.73 % | $ 1.8 B | Nasdaq Global Select Market,SPB | ||
|
Global Blood Therapeutics
GBT
|
- | - | $ 4.62 B | Nasdaq Global Select Market,SPB | ||
|
Sutro Biopharma
STRO
|
$ 8.79 | -5.79 % | $ 74.7 M | Nasdaq Global Select Market | ||
|
Shattuck Labs
STTK
|
$ 5.55 | 1.09 % | $ 386 M | Nasdaq Global Select Market | ||
|
Supernus Pharmaceuticals
SUPN
|
$ 40.79 | 0.22 % | $ 2.3 B | Nasdaq Global Select Market,SPB | ||
|
Savara
SVRA
|
$ 4.53 | 7.23 % | $ 1.01 B | Nasdaq Global Select Market | ||
|
China SXT Pharmaceuticals
SXTC
|
$ 3.49 | -14.88 % | $ 2.37 M | Nasdaq Global Select Market | ||
|
Takeda Pharmaceutical Company Limited
TAK
|
$ 20.45 | 1.01 % | $ 32.3 B | NYSE | ||
|
Inozyme Pharma
INZY
|
- | - | $ 207 M | Nasdaq Global Select Market | ||
|
BioCardia
BCDA
|
$ 0.89 | -3.28 % | $ 5.93 M | Nasdaq Global Select Market | ||
|
CNS Pharmaceuticals
CNSP
|
$ 4.53 | -8.85 % | $ 2.01 M | Nasdaq Capital Market | ||
|
Cocrystal Pharma
COCP
|
$ 0.97 | 2.11 % | $ 11 M | Nasdaq Capital Market | ||
|
Protara Therapeutics
TARA
|
$ 2.36 | 1.07 % | $ 101 M | Nasdaq Global Market | ||
|
Tarsus Pharmaceuticals
TARS
|
$ 69.94 | 2.55 % | $ 2.92 B | Nasdaq Global Select Market | ||
|
Idera Pharmaceuticals
IDRA
|
- | -23.04 % | $ 26.6 M | Nasdaq Global Select Market | ||
|
Teva Pharmaceutical Industries Limited
TEVA
|
$ 40.03 | 1.57 % | $ 45.8 B | NYSE | ||
|
Collegium Pharmaceutical
COLL
|
$ 23.21 | 1.09 % | $ 735 M | Nasdaq Global Select Market | ||
|
NanoString Technologies
NSTG
|
- | -37.43 % | $ 5.1 M | Nasdaq Global Select Market | ||
|
Corcept Therapeutics Incorporated
CORT
|
$ 87.25 | 1.62 % | $ 9.06 B | Nasdaq Capital Market,SPB | ||
|
TG Therapeutics
TGTX
|
$ 54.79 | 1.14 % | $ 7.91 B | Nasdaq Capital Market | ||
|
Humanigen
HGEN
|
- | -81.12 % | $ 4.28 M | Nasdaq Global Select Market | ||
|
Sorrento Therapeutics
SRNE
|
- | -29.58 % | $ 126 M | Nasdaq Global Select Market | ||
|
Surface Oncology
SURF
|
- | - | $ 59.7 M | Nasdaq Global Select Market | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
$ 4.0 | -1.36 % | $ 53.3 M | Nasdaq Global Market | ||
|
Sierra Oncology
SRRA
|
- | -0.05 % | $ 1.34 B | Nasdaq Global Select Market | ||
|
Tonix Pharmaceuticals Holding Corp.
TNXP
|
$ 5.31 | 2.42 % | $ 45.2 M | Nasdaq Global Select Market | ||
|
Atea Pharmaceuticals
AVIR
|
$ 4.16 | 2.97 % | $ 339 M | Nasdaq Global Select Market | ||
|
Tenax Therapeutics
TENX
|
$ 1.65 | -4.07 % | $ 64.7 M | Nasdaq Global Select Market | ||
|
Vaccinex
VCNX
|
- | -61.37 % | $ 654 K | Nasdaq Global Select Market | ||
|
Trevi Therapeutics
TRVI
|
$ 12.51 | -0.83 % | $ 1.69 B | Nasdaq Global Market | ||
|
Nymox Pharmaceutical Corporation
NYMX
|
- | -19.68 % | $ 18.4 M | Nasdaq Capital Market | ||
|
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | ||
|
Taysha Gene Therapies
TSHA
|
$ 4.0 | 0.88 % | $ 1.28 B | Nasdaq Global Select Market | ||
|
Jounce Therapeutics
JNCE
|
- | - | $ 98.4 M | Nasdaq Global Select Market | ||
|
Verona Pharma plc
VRNA
|
- | - | $ 69.7 B | Nasdaq Global Select Market |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.